FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1045-1046 October 5, 2000 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Canto, J. G. Related Article by Ryan, E. T.

To the Editor: In their recommendations for travelers, Ryan and Kain (June 8 issue)¹ unfortunately do not include sufficient information about the adverse effects of mefloquine (Lariam). Recent studies from Spain, Sweden, and California^2,3,4 found that one in five people discontinues use of this drug because of neuropsychological symptoms. A study from Denmark found that the rate of central nervous system symptoms was higher in people taking mefloquine than in those taking other drugs as prophylaxis against malaria and that "when symptoms develop, they are perceived as more severe."⁵ Last year, the product information for Lariam was completely revised and . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.